Development and validation of a multiplex HPLC-MS/MS assay for the monitoring of JAK inhibitors in patient plasma
出版年份 2023 全文链接
标题
Development and validation of a multiplex HPLC-MS/MS assay for the monitoring of JAK inhibitors in patient plasma
作者
关键词
-
出版物
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
Volume -, Issue -, Pages 123917
出版商
Elsevier BV
发表日期
2023-10-29
DOI
10.1016/j.jchromb.2023.123917
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
- (2023) Ohsang Kwon et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease
- (2023) Edward V. Loftus et al. NEW ENGLAND JOURNAL OF MEDICINE
- A high-throughput UHPLC-MS/MS method for the determination of eight anti-tumor drugs in plasma
- (2023) Yao Liu et al. ANALYTICAL BIOCHEMISTRY
- Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis
- (2022) Jessica Wojciechowski et al. CLINICAL PHARMACOKINETICS
- Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
- (2022) Steven R. Ytterberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy Individuals
- (2022) Xiaoxing Wang et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- Evaluation of the inhibitory effect of quercetin on the pharmacokinetics of tucatinib in rats by a novel UPLC–MS/MS assay
- (2022) Ying Zhang et al. PHARMACEUTICAL BIOLOGY
- Upadacitinib Is Safe and Effective for Crohn’s Disease: Real-World Data from a Tertiary Center
- (2022) Cindy Traboulsi et al. DIGESTIVE DISEASES AND SCIENCES
- Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn’s disease: systematic review and network meta-analysis
- (2022) Brigida Barberio et al. GUT
- Rheumatoid arthritis: advances in treatment strategies
- (2022) Peeyush Prasad et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis
- (2022) Alexandre Sepriano et al. ANNALS OF THE RHEUMATIC DISEASES
- Upadacitinib Population Pharmacokinetics and Exposure-Response Relationships in Ulcerative Colitis Patients
- (2022) Ana Victoria Ponce-Bobadilla et al. CLINICAL PHARMACOKINETICS
- Frequency of Prescription Claims for Drugs that May Interact with Janus Kinase Inhibitors Among Patients with Rheumatoid Arthritis in the US
- (2021) Alison Walton et al. Rheumatology and Therapy
- In vivo Pharmacokinetic Drug-Drug Interaction Studies Between Fedratinib and Antifungal Agents Based on a Newly Developed and Validated UPLC/MS-MS Method
- (2021) Congrong Tang et al. Frontiers in Pharmacology
- Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis
- (2021) Camille Vong et al. Clinical Pharmacology in Drug Development
- Development and clinical validation of a simple and fast UPLC-ESI-MS/MS method for simultaneous quantification of nine kinase inhibitors and two antiandrogen drugs in human plasma: Interest for their therapeutic drug monitoring
- (2021) Benoit Llopis et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
- (2021) Thomas Bieber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Upadacitinib Pharmacokinetics and Exposure‐Response Analyses of Efficacy and Safety in Psoriatic Arthritis Patients – Analyses of Phase 3 Clinical Trials
- (2021) Elena Muensterman et al. CTS-Clinical and Translational Science
- Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease
- (2021) Robert Zeiser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS
- (2021) Jens Martens-Lobenhoffer et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Effects of Renal Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites
- (2021) Ellen Q. Wang et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Validation of enantioseparation and quantitation of an active metabolite of abrocitinib in human plasma
- (2021) Sakambari Tripathy et al. Bioanalysis
- Influence of Inflammation on Cytochromes P450 Activity in Adults: A Systematic Review of the Literature
- (2021) Camille Lenoir et al. Frontiers in Pharmacology
- The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib
- (2020) Thierry Buclin et al. Frontiers in Pharmacology
- Critical Assessment of Pharmacokinetic Drug–Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment
- (2020) Vijayabhaskar Veeravalli et al. DRUG SAFETY
- Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
- (2020) Robert Zeiser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacokinetics, Safety, and Tolerability of Single‐ and Multiple‐Dose Once‐Daily Baricitinib in Healthy Chinese Subjects: A Randomized Placebo‐Controlled Study
- (2020) Xia Zhao et al. Clinical Pharmacology in Drug Development
- Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I–III Clinical Trials
- (2019) Ben Klünder et al. CLINICAL PHARMACOKINETICS
- Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects
- (2019) Vassilios Aslanis et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases
- (2019) Kellyn Moran et al. ADVANCES IN THERAPY
- Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
- (2019) Ken Ogasawara et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Upadacitinib in Adults With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Randomized, Placebo-Controlled Trial
- (2019) Emma Guttman-Yassky et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials
- (2019) Ahmed Nader et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Clinical Pharmacokinetics of Upadacitinib: Review of Data Relevant to the Rheumatoid Arthritis Indication
- (2019) Mohamed-Eslam F. Mohamed et al. CLINICAL PHARMACOKINETICS
- Effective quantification of 11 tyrosine kinase inhibitors and caffeine in human plasma by validated LC-MS/MS method with potent phospholipids clean-up procedure. Application to therapeutic drug monitoring
- (2019) Dora Koller et al. TALANTA
- Development and Validation of a Simultaneous Quantification Method of Ruxolitinib, Vismodegib, Olaparib, and Pazopanib in Human Plasma Using Liquid Chromatography Coupled With Tandem Mass Spectrometry
- (2018) Claire Pressiat et al. THERAPEUTIC DRUG MONITORING
- From method validation to result assessment: Established facts and pending questions
- (2018) Serge Rudaz et al. TRAC-TRENDS IN ANALYTICAL CHEMISTRY
- Development and validation of a rapid and sensitive UPLC-MS/MS assay for the quantification of tofacitinib in human plasma
- (2018) Kirtikumar D. Bharwad et al. BIOMEDICAL CHROMATOGRAPHY
- UPLC-MS/MS method for the simultaneous determination of imatinib, voriconazole and their metabolites concentrations in rat plasma
- (2018) Ren-ai Xu et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
- (2017) Peter C. Taylor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
- (2017) Claire N Harrison et al. Lancet Haematology
- An LC-MS/MS method for rapid and sensitive high-throughput simultaneous determination of various protein kinase inhibitors in human plasma
- (2016) Ali S. Abdelhameed et al. BIOMEDICAL CHROMATOGRAPHY
- Biologic agents for IBD: practical insights
- (2015) Silvio Danese et al. Nature Reviews Gastroenterology & Hepatology
- Derivation of uncertainty functions from validation studies in biological fluids: Application to the analysis of caffeine and its major metabolites in human plasma samples
- (2014) Anne-Laure Gassner et al. JOURNAL OF CHROMATOGRAPHY A
- Population Pharmacokinetic Analysis of Orally-Administered Ruxolitinib (INCB018424 Phosphate) in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia Myelofibrosis (PET MF)
- (2013) Xuejun Chen et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Liver kidney microsomal type 1 antibodies reduce the CYP2D6 activity in patients with chronic hepatitis C virus infection
- (2012) F. Girardin et al. JOURNAL OF VIRAL HEPATITIS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started